Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma
{{output}}
Long-term follow-up of the CASSIOPEIA trial (NCT02541383) demonstrated superior progression-free survival (PFS) with daratumumab, both in combination with bortezomib, thalidomide, and dexamethasone during induction and consolidation, and during maintenance the... ...
